These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32935478)

  • 41. Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis.
    Su C; Zhang P; Liu J; Cao Y
    Biomed Pharmacother; 2017 Apr; 88():521-528. PubMed ID: 28129624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.
    Kitamura H; Ohno Y; Toyoshima Y; Ohtake J; Homma S; Kawamura H; Takahashi N; Taketomi A
    Cancer Sci; 2017 Oct; 108(10):1947-1952. PubMed ID: 28749573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The emerging role of interleukin-37 in cardiovascular diseases.
    Zhuang X; Wu B; Li J; Shi H; Jin B; Luo X
    Immun Inflamm Dis; 2017 Sep; 5(3):373-379. PubMed ID: 28548248
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer.
    Feng X; Liu H; Chu X; Sun P; Huang W; Liu C; Yang X; Sun W; Bai H; Ma Y
    Acta Biomater; 2019 Dec; 100():316-325. PubMed ID: 31542504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IL-10: master switch from tumor-promoting inflammation to antitumor immunity.
    Oft M
    Cancer Immunol Res; 2014 Mar; 2(3):194-9. PubMed ID: 24778315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual role of IL-37 in the progression of tumors.
    Zhu Y; Qin H; Ye K; Sun C; Qin Y; Li G; Wang H; Wang H
    Cytokine; 2022 Feb; 150():155760. PubMed ID: 34800851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interleukin-9 promotes tumorigenesis through augmenting angiogenesis in non-small cell lung cancer.
    He J; Wang L; Zhang C; Shen W; Zhang Y; Liu T; Hu H; Xie X; Luo F
    Int Immunopharmacol; 2019 Oct; 75():105766. PubMed ID: 31352324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.
    Weinstein AM; Giraldo NA; Petitprez F; Julie C; Lacroix L; Peschaud F; Emile JF; Marisa L; Fridman WH; Storkus WJ; Sautès-Fridman C
    Cancer Immunol Immunother; 2019 Jan; 68(1):109-120. PubMed ID: 30315348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis.
    Liang W; Ferrara N
    Cancer Immunol Res; 2016 Feb; 4(2):83-91. PubMed ID: 26839309
    [TBL] [Abstract][Full Text] [Related]  

  • 50. γδ T Cells: Unexpected Regulators of Cancer Development and Progression.
    Fleming C; Morrissey S; Cai Y; Yan J
    Trends Cancer; 2017 Aug; 3(8):561-570. PubMed ID: 28780933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interleukin-33 and ST2 Signaling in Tumor Microenvironment.
    Hong J; Kim S; Lin PC
    J Interferon Cytokine Res; 2019 Jan; 39(1):61-71. PubMed ID: 30256696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin 32, inflammation and cancer.
    Hong JT; Son DJ; Lee CK; Yoon DY; Lee DH; Park MH
    Pharmacol Ther; 2017 Jun; 174():127-137. PubMed ID: 28223235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. T11 target structure induced modulations of the pro-inflammatory and anti-infammatorycytokine expressions in experimental animals for glioma abrogation.
    Singh MK; Chaudhuri S; Bhattacharya D; Kumar P; Datta A; Chaudhuri S
    Int Immunopharmacol; 2015 Feb; 24(2):198-207. PubMed ID: 25528475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interleukin-8 in the Tumor Immune Niche: Lessons from Comparative Oncology.
    Kim JH
    Adv Exp Med Biol; 2020; 1240():25-33. PubMed ID: 32060885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IL-27 in tumor immunity and immunotherapy.
    Murugaiyan G; Saha B
    Trends Mol Med; 2013 Feb; 19(2):108-16. PubMed ID: 23306374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis.
    Ribatti D
    Immunol Lett; 2013 May; 152(2):83-8. PubMed ID: 23685256
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.
    Carnemolla B; Borsi L; Balza E; Castellani P; Meazza R; Berndt A; Ferrini S; Kosmehl H; Neri D; Zardi L
    Blood; 2002 Mar; 99(5):1659-65. PubMed ID: 11861281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity.
    Campesato LF; Silva APM; Cordeiro L; Correa BR; Navarro FCP; Zanin RF; Marçola M; Inoue LT; Duarte ML; Molgora M; Pasqualini F; Massara M; Galante P; Barroso-Sousa R; Polentarutti N; Riva F; Costa ET; Mantovani A; Garlanda C; Camargo AA
    Oncotarget; 2017 Jul; 8(30):49470-49483. PubMed ID: 28533483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
    Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.